Evidence mapPaperPMID 41779280Full record

ReviewReviews in endocrine & metabolic disorders2026

Hypothalamic wars: the last nanodelivery.

Sajid Fazal, Jane Jose Vattathara, Miguel López

Abstract readReview
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sajid FazalNeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain. sajid.fazal@usc.es.ORCID 0000-0002-4752-2813
Jane Jose VattatharaNeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain.ORCID 0009-0006-7285-690X
Miguel LópezNeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain. m.lopez@usc.es.ORCID 0000-0002-7823-1648

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hypothalamus plays important roles in maintaining overall body homeostasis and energy balance. Disruption of its normal functioning has been associated with the onset of various metabolic disorders in the body that arise from several genetic, immunological, and environmental factors or their combination. To combat this, developing treatment strategies that modulate the activity of the hypothalamus could be advantageous. Here, understanding the hypothalamus’s complex structure and function within the context of regulation of energy balance is important to identify treatment targets and to explore opportunities to modulate key metabolic pathways. Moreover, the unique sensitive position of the hypothalamus in the brain necessitates that treatment strategies that are developed are highly effective and specific, and do not cause any untoward effects at neighboring regions of the brain. This is further complicated by its protection through the blood-brain barrier (BBB) that highly regulates the entry of materials from the periphery, allowing entry of molecules only under specific conditions. In this regard, advanced multifunctional nanoparticulate drug-delivery systems can be of benefit as they have been explored for brain specific delivery. For this, nanoparticle chemistry, specific ligand expression, BBB penetration capability, biocompatibility, and immunogenicity among other physicochemical properties are important parameters that govern brain specific delivery. In this review, the role of hypothalamus in regulating energy metabolism, its structure and function and the effect of dysfunction on the onset of metabolic disorders are summarized. Furthermore, the use of nanoparticles for brain targeting and hypothalamic regulation, such as small extracellular vesicles targeting AMP-activated protein kinase (AMPK), along with the future of nanoparticle-based modulation of the hypothalamus is also discussed.

Indexed as

Drug Delivery SystemsHypothalamusMetabolic DiseasesNanoparticlesAnimalsBlood-Brain BarrierEnergy MetabolismHumans

Identifiers

PMID41779280
PMCPMC13246852

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.